H Lundbeck A/S
(OTCOTHER: HLUKF)
+0.39
+1.98%
| Exchange: | OTCOTHER |
| Stock: | H Lundbeck A/S |
| Industry: | NA |
| Employees: | NA |
| H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. The Company is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, including Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. The Company’s product portfolio includes such pharmaceuticals, as Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. Additionally, the Company had a number of products in development phases. As of December 31, 2012, it was active through subsidiaries in 57 countries, including Argentina, Australia, Denmark, China, Russia, the United States and the United Kingdom, among others. |
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations data provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.
Japanese stock price data provided by Nomura Research Institute Ltd.; quotes delayed 20 minutes. Canadian fund data provided by CANNEX Financial Exchanges Ltd.
